GL1X · GenesisL1 explorer

MolNFT v1 · #127497 · protein

Homodimerization of TIE2 fibronectin-like domains 1-3 in space group C2

5MYA · Angiopoietin-1 receptor: “Homodimerization of TIE2 fibronectin-like domains 1-3 in space group C2”. X-ray diffraction, 3 ligands (NAG, BMA, MAN), 2 pockets (best druggability 0.55). MolNFT v1 #127497 on GenesisL1: 3D structure…

PDB
5MYA
Type
protein
Length
483 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Angiopoietin-1 receptor
EC
2.7.10.1
UniProt
Q02763
Ligands
NAG, BMA, MAN
Pockets
2 · best druggability 0.55

Structure

x-ray diffraction · 2 distinct chains · 0% helix, 46% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAngiopoietin-1 receptor (EC 2.7.10.1)protein2920% helix, 46% strandQ02763
BAngiopoietin-1 receptor (EC 2.7.10.1)protein1910% helix, 45% strandQ02763

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 10 copies · chains A, B
  • BMA · beta-D-mannopyranose · sugar · 2 copies
  • MAN · alpha-D-mannopyranose · sugar

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11500.550.8125empty
21370.500.7922empty

Interfaces

1 interface between chains.

  • A–B · 755 Ų buried · 12 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 7 glycan (N-glycosylation).

Compared structures

  • 5MYA · Homodimerization of Tie2 Fibronectin-like domains 1-3 in space group C2 · the same entry in another collection · chain A against A, TM-score 1.00
  • Q02763 · AlphaFold monomer V2.0 prediction for angiopoietin-1 receptor (Q02763) · a predicted model of the same protein · chain B against A, TM-score 0.95

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.